We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Adaptimmune Therapeutics PLC | NASDAQ:ADAP | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.015 | 1.30% | 1.165 | 1.16 | 1.17 | 1.23 | 1.15 | 1.23 | 444,059 | 18:33:45 |
By Denny Jacob
International stocks trading in New York closed mixed on Friday.
The S&P/BNY Mellon index of American depositary receipts ticked down 0.1% to 155.61. The European index edged up 0.6% to 145.11. The Asian index lost 1.4% to 186.11. The Latin American index moved up 0.7% to 227.71, while the emerging-markets index retreated 1.1% to 320.30.
Adaptimmune Therapeutics Plc was among those whose ADRs traded actively.
The novel cancer immunotherapy products developer fell 2.7% after it said Friday that data from multiple solid tumor indications confirms that MAGE-A4 is a broadly expressed cancer target for SPEAR T-cell therapy.
Molecular diagnostics company Genetic Technologies moved down 3.8% after it provided its year to date results for the nine months ended March 31, noting that its product geneType Multi-Risk Test received approval for commercial release and that the U.S. Patent and Trademark Office granted a patent for the geneType Covid-19 Risk Test.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 08, 2022 16:25 ET (20:25 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Adaptimmune Therapeutics Chart |
1 Month Adaptimmune Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions